Tag Archives: Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) Received its Third Buy in a Row

After Jefferies and RBC Capital gave Vertex Pharmaceuticals (NASDAQ: VRTX) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Vertex Pharmaceuticals today and set a price

RBC Capital Remains a Buy on Vertex Pharmaceuticals

In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX), with a price target of $203. The company’s shares opened today at $178.61, close to its 52-week high of $183.39. According

Oppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today. The company’s shares closed yesterday at $147.59. According to TipRanks.com, Singh is a 4-star analyst with an average return of 11.3% and a 42.6% success rate.

Cowen & Co. Keeps a Buy Rating on Vertex Pharmaceuticals

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) yesterday and set a price target of $200. The company’s shares opened today at $156.05. According to TipRanks.com, Nadeau is a 5-star analyst with an

Maxim Group Reaffirms Their Buy Rating on Vertex Pharmaceuticals

Maxim Group analyst Jason McCarthy maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $200. The company’s shares closed yesterday at $158.81. McCarthy commented: “Vertex reported 1Q18 with revenue of $641M, beating consensus

JMP Securities Sticks to Its Hold Rating for Vertex Pharmaceuticals

JMP Securities analyst Liisa Bayko reiterated a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $211. The company’s shares opened today at $151.40. According to TipRanks.com, Bayko is a 5-star analyst with an average